We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
KAI Pharmaceuticals Announces Initiation of Second Phase 2 Study of KAI-4169
News

KAI Pharmaceuticals Announces Initiation of Second Phase 2 Study of KAI-4169

KAI Pharmaceuticals Announces Initiation of Second Phase 2 Study of KAI-4169
News

KAI Pharmaceuticals Announces Initiation of Second Phase 2 Study of KAI-4169

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "KAI Pharmaceuticals Announces Initiation of Second Phase 2 Study of KAI-4169"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The single-arm, open-label, multicenter, dose-titration study is designed to evaluate the effect of three times weekly intravenous bolus administration of KAI-4169 over a 12-week treatment period as assessed by percent change in parathyroid hormone (PTH) from baseline at the end of treatment. Secondary endpoints include proportion of subjects with greater-than or equal to 30% reduction in PTH from baseline, the proportion of subjects with PTH less-than or equal to 300 pg/mL and the mean change from baseline in serum calcium and phosphorus.

Steven James, President and CEO of KAI, commented, "We are proud of the momentum and continued progress of KAI-4169, our lead program. We recently reported results of the first Phase 2 study of KAI-4169 at the annual meeting of the American Society of Nephrology in a late breaker poster presentation. We believe KAI-4169 may lead to greatly improved care for patients, and we look forward to reporting continued positive results and progress of our program."

Advertisement